Stahlnebel Black Selket - Russian Roulette - .44 Blast remix by SIN D.N.A.
Uploader: ebmelectrofreak https://www.facebook.com/ebmelectrofreak https://www.facebook.com/stahlnebel.blackselket?fref=ts http://stahlnebelblackselket.bandc...
By: ebmelectrofreak1
See original here:
Stahlnebel & Black Selket - Russian Roulette - .44 Blast remix by SIN D.N.A. - Video
British Intelligence Advisor Michael Shrimpton: Obama #39;s DNA Doesn #39;t Match Grandparents
British Intelligence Advisor Barrister Michael Shrimpton presented a report in which he indicated that Barack Hussein Obama was born in Kenya in 1960, not 19...
By: Tim Brown
Visit link:
British Intelligence Advisor Michael Shrimpton: Obama's DNA Doesn't Match Grandparents - Video
CE2013-I - DNA-schade maakt oud
Uitwerking van opdracht 5 - DNA-schade maakt oud van het CE Biologie 2013-I.
By: NGbiologie
See original here:
CE2013-I - DNA-schade maakt oud - Video
IOS Plague Inc DNA Hack No Survey
igamegaurdian hack for Plague Inc. No Downloads. No Surveys. You must be jail broken and install the source: http://yuan.duowan.com/ for ios7 igame guardian ...
By: The Crit Reaper
Read more:
IOS Plague Inc DNA Hack No Survey - Video
Westport, CT - infoZine - E/The Environmental Magazine - "Synthetic biology" (or "synbio") refers to the design and fabrication of novel biological parts, devices and systems that do not otherwise occur in nature. Many see it as an extreme version of genetic engineering (GE). But unlike GE, whereby genetic information with certain desirable traits is inserted from one organism into another, synbio uses computers and chemicals to create entirely new organisms.
Proponents of synbio, which include familiar players such as Cargill, BP, Chevron and Du Pont, tout its potential benefits. According to the Synthetic Biology Engineering Research Center (SYNBERC), a consortium of leading U.S. researchers in the field, some promising applications of synthetic biology include alternatives to rubber for tires, tumor-seeking microbes for treating cancer, and photosynthetic energy systems. Other potential applications include using synbio to detect and remove environmental contaminants, monitor and respond to disease and develop new drugs and vaccines.
"This is the first major use of a synbio ingredient in food, and dozens of other flavors and food additives are in the pipeline, so synbio vanilla could set a dangerous precedent for synthetic genetically engineered ingredients to sneak into our food supply and be labeled as natural," reports Friends of the Earth (FoE), a leading environmental group. "Synthetic biology vanillin poses several human health, environmental and economic concerns for consumers, food companies and other stakeholders."
For example, FoE worries that synbio vanilla (and eventually other synthetic biology additives) could exacerbate rainforest destruction while harming sustainable farmers and poor communities around the world. "Synbio vanillacould displace the demand for the natural vanilla market," reports FoE. "Without the natural vanilla market adding economic value to the rainforest in these regions, these last standing rainforests will not be protected from competing agricultural markets such as soy, palm oil and sugar." Critics of synbio also worry that releasing synthetic life into the environment, whether done intentionally or accidentally, could have adverse effects on our ecosystems.
Despite these risks, could the rewards of embracing synthetic biology be great? Could it help us deal with some of the tough issues of climate change, pollution and world hunger? Given that the genie is already out of the bottle, perhaps only time will tell.
Related Links SYNBERC: http://www.synberc.org FoE: http://www.foe.org Evolva: http://www.evolva.com
Send your environmental questions to: EarthTalk, c/o E - The Environmental Magazine, P.O. Box 5098, Westport, CT 06881;
More:
F215 genetic engineering pt 2 njlm
f215 pcr plasmids.
By: Neil Moore
Read the original here:
F215 Genetic Engineering pt1 njlm
Autosave 250214-1616.
By: Neil Moore
View post:
Genetic Engineering at Cedar Crest
By: Cedar Crest College
Go here to see the original:
Rinehart Screencast Genetic Engineering
Video notes on Genetic Engineering.
By: Brad Rinehart
Read more here:
Demand for food free of genetically modified organisms is growing fast and nowhere stronger than in British Columbia.
North American retail sales of Non-GMO Project verified foods have grown more than 300 per cent in three years, from $1.3 billion in 2011 to $5 billion today.
Products that display both an organic and non-GMO certification are out-selling their competitors five to one at Whole Foods Markets, company spokesman Joe Kennedy recently told a conference organized by the B.C. Food Processors Association.
The market share for organic groceries in B.C. is already double that of the rest of Canada, according to the Canada Organic Trade Association. Its 2013 market report found that two thirds of British Columbians buy organic foods each week and more than half of those surveyed said they want to avoid GMOs in their food.
A recent Ipsos Reid poll of 1,200 Canadians conducted for BioAccess Commercialization Centre, a non-profit organization that supports the natural foods industry, suggests that British Columbians are more likely to look for a non-GMO label than other Canadians.
But the Ipsos Reid survey also found widespread confusion about which crops, fruit and vegetables are likely to be the product of genetic engineering.
More than 60 per cent of respondents identified strawberries as a product of genetic engineering, but there are no commercially grown GE strawberries. Only 42 per cent identified tofu as a GMO product, despite the fact that more than 90 per cent of soybeans grown in North America are genetically engineered.
So many shoppers are convinced that perfect, red hothouse tomatoes are the result of genetic engineering that B.C.-based grower Houweling's Tomatoes obtained Non-GMO Project verification. There are no GE tomatoes on store shelves in Canada.
Explaining GMOs Genetically engineered or GE lifeforms - popularly known as genetically modified organisms or GMOs - are created when the genetic code of an organism is altered to express a desirable trait or when code containing undesirable traits is silenced or removed. Much of the opposition to genetic engineering of foods is focused on the practice of inserting genetic code from one organism into another, which cannot occur under natural circumstances. At its heart, genetic engineering is a short cut that scientists devised to speed up the work of selective breeding of plants into more useful and productive forms and to resist threats from the environment. Such selective breeding has been going on for most of human history and nearly every food crop grown today has been genetically modified through this older process.
What could have been a public relations coup for biotechnology with the promise to provide the world more nutritious, less expensive food using fewer resources has become a nasty fight driven by dislike of corporate power and fears of uncontrolled environmental and health effects. Companies such as Monsanto, Syngenta, Dupont and Bayer CropScience, which dominate the biotechnology landscape with billions of dollars in sales, are fighting allegations that they are using intellectual property law to monopolize the world's seeds and by extension the world's food supply.
What are GMOs?
Genetically modified organisms - or more precisely genetically engineered organisms - are created when the genetic code of a life form is altered in a way that is not possible by natural processes. Genetic code may be removed, silenced or replaced by genetic code from another organism to promote the expression of desirable traits such as resistance to pests, or eliminate undesirable traits, such as susceptibility to disease. One of the first widely used GE crops was created by fusing a gene derived from a bacteria into the DNA of soybeans, making them resistant to the herbicide Roundup.
Bt corn was made resistant to insects by inserting a gene from a naturally occurring soil bacterium that produces a protein toxic to insect larvae, but harmless to mammals. A spray version of Bt toxin has been in use for more than 50 years. New technologies allow scientists to rewrite specic sections of genetic code without introducing outside genetic material, a technique recently used with success on monkeys.
Are certified organic and Non-GMO Project-verified foods GMO-free?
No. In the real world, pollen drifts, supply chains are shared and a low-level presence of GMOs in much of our food is a fact of life. This is why the Canadian government does not allow products to be labelled "GE free" or "GMO free."
But certified foods almost certainly contain less GE material than foods that do not carry certifi-cation. Products certified as organic may not be grown from GE seed nor can they contain ingredients derived from GMOs. However, organic certification is process-based, meaning that growers and processors must adhere to certain practices, which may not include testing for the low-level presence of GMOs. Detectable residue from GMOs does not necessarily constitute a violation of certification standards. Non-GMO Project verification does require testing for ingredients such as corn or soy, which have widely grown GE versions. Supply chain segregation, traceability and quality controls are employed to reduce risk that GMOs are present in the final product. The Non-GMO Project uses an "action threshold" of 0.9 per cent GMO. At or below is OK, above is not. The European Union employs the same threshold for food imports.
Are farmers starting to abandon GE crops?
Maybe, maybe not. It seems as if every anti-GMO activist has heard of farmers turning away from GE crops. So far, acreage numbers and biotech companies' balance sheets suggest otherwise. In 2012, more than 97 per cent of canola grown in Canada was GE, according to the International Service for the Acquisition of Agri-Biotech Applications. Global acreage under biotech crops rose six per cent, reaching a record 170 million acres in 2012, 52 per cent of that in the developing world. Global GE acreage increases in 2012 over the previous year include canola (+5%), maize (+4%), cotton (+7%) and soybeans (+8%).
Where are the GMOs hiding?
In plain sight. A handful of genetically engineered foods are in plain sight. Many thousands of ready-to-eat and processed foods contain ingredients such as oil, sugar, starch and protein made from the main GE commodity crops: corn, soy, sugar beets, canola and cottonseed. None of the genetically engineered whole foods or foods containing ingredients derived from GE commodity crops is required to be labelled in the United States or Canada.
Read more here:
What are GMOs and why are they here?
Environment Minister M Veerappa Moily has cleared a Genetic Engineering Appraisal Committee (GEAC) decision to allow gene modification field trials for certain food crops after the same was put on hold for about a year by his predecessor, Jayanthi Natarajan.
Environment Minister M Veerappa Moily has cleared a Genetic Engineering Appraisal Committee (GEAC) decision to allow gene modification field trials for certain food crops after the same was put on hold for about a year by his predecessor, Jayanthi Natarajan.
While giving his nod, Moily, however, sought to downplay the approval row, saying there was some "misunderstanding" over the issue and there was no "embargo" from Supreme Court on such trials. The minister's nod will pave the way for GM field trails for rice, wheat, maize and cotton.
Moily, however, made it clear that the trials are subject to approval by state governments and fulfilment of certain conditions.
The clearance will enable companies such as Bayer Bioscience, Mahyco and BASF and Monsanto India to carry out field trials for the crops. Bayer Bioscience, for example, has been given clearance to test GM rice across the country.
Earlier, Natarajan had blocked the approval obtained by GEAC in March of last year, reportedly because the issue was pending in the apex court.
But Moily said he had examined the case with officials and found that there was no embargo on the clearance by Supreme Court, Moily said.
"It is a report from a statutory committee. I don't think a ministry or a minister will have any business holding it back. We can't do that. We have to work with the rules... and the law of the land is same for everyone. That is why, as a law-abiding minister, I approved it," Moily told reporters here.
The minister also said that the Environment Ministry, Agriculture Ministry and the Department of Biotechnology had a "common position" on the issue, which would be placed before Supreme Court. Natarajan had, in fact, not "disagreed" with the decision of the GEAC, he further stated.
The next meeting of GEAC has been called on March 21 to discuss some more issues, he said.
Excerpt from:
Enviornment ministry green light for gene modification field trials: Veerappa Moily
Environment Minister M Veerappa Moily has cleared a Genetic Engineering Appraisal Committee (GEAC) decision to allow gene modification field trials for certain food crops after the same was put on hold for about a year by his predecessor, Jayanthi Natarajan.
While giving his nod, Moily, however, sought to downplay the approval row, saying there was some "misunderstanding" over the issue and there was no "embargo" from Supreme Court on such trials.
The minister's nod will pave the way for GM field trails for rice, wheat, maize and cotton.
Moily, however, made it clear that the trials are subject to approval by state governments and fulfilment of certain conditions.
The clearance will enable companies such as Bayer Bioscience, Mahyco and BASF and Monsanto India to carry out field trials for the crops. Bayer Bioscience, for example, has been given clearance to test GM rice across the country.
Earlier, Natarajan had blocked the approval obtained by GEAC in March of last year, reportedly because the issue was pending in the apex court.
But Moily said he had examined the case with officials and found that there was no embargo on the clearance by Supreme Court, Moily said.
"It is a report from a statutory committee. I don't think a ministry or a minister will have any business holding it back. We can't do that. We have to work with the rules... And the law of the land is same for everyone. That is why, as a law-abiding minister, I approved it," Moily told reporters here.
The minister also said that the Environment Ministry, Agriculture Ministry and the Department of Biotechnology had a "common position" on the issue, which would be placed before Supreme Court.
Natarajan had, in fact, not "disagreed" with the decision of the GEAC, he further stated.
See the original post here:
Environment Min Nod for Gene Modification Field Trials
2:10 How To Survive Armageddon, Peter Kling 20Feb2014
If you #39;re reading this at http://www.guerillamedia.co.nz click "Original Article" on the bottom right for the video. PLEASE SUBSCRIBE AND GIVE A THUMBS UP Wa...
By: Vincent Eastwood
Originally posted here:
2:10 How To Survive Armageddon, Peter Kling 20Feb2014 - Video
How Synthetic Biology Is Exploring Biological Complexity: Sean Ward at TEDxVilnius
Before founding Synthace, Sean was a Research Associate in Bioinformatics at University College London, where he conducted research into protein folding, pro...
By: TEDxTalks
View post:
How Synthetic Biology Is Exploring Biological Complexity: Sean Ward at TEDxVilnius - Video
PUBLIC RELEASE DATE:
26-Feb-2014
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, February 26, 2014Whole body cooling in comatose patients who have suffered a heart attack can limit the damage to brain tissue caused by the restoration of blood flow and oxygen. But new data indicate that in certain patients therapeutic hypothermia is less effective and may even worsen neurological outcomes, as described in an article in Therapeutic Hypothermia and Temperature Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Therapeutic Hypothermia and Temperature Management website at http://www.liebertpub.com/ther.
Timothy Mader and coauthors representing the CARES Surveillance Group (Baystate Medical Center, Tufts University School of Medicine, Springfield, MA; OptiStatim, LLC, Longmeadow, MA; Emory University School of Medicine, Atlanta, GA) conclude that while therapeutic hypothermia may be effective for certain patient subsets, "more uniform and rigid guidelines for application are needed to assure more appropriate application."
The authors measured neurological outcomes at hospital discharge among a large group of adults who suffered heart attacks out of the hospital. They compared the results among patients whose hearts resumed beating with or without the need to be shocked and report their findings in the article "Comparative Effectiveness of Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest: Insight from a Large Data Registry."
"This manuscript is important to the field of therapeutic hypothermia in that it points to a need for additional research to be conducted and guidelines developed to clarify specific patient populations that will most benefit from cooling strategies," says W. Dalton Dietrich, III, PhD, Editor-in-Chief of the Journal and Kinetic Concepts Distinguished Chair in Neurosurgery, Professor of Neurological Surgery, Neurology and Cell Biology, University of Miami Leonard M. Miller School of Medicine.
###
About the Journal
Therapeutic Hypothermia and Temperature Management provides a strong multidisciplinary forum to advance the understanding of therapeutic hypothermia. Novel findings from translational preclinical investigations as well as clinical studies and trials will be featured in articles, state-of-the-art reviews, provocative roundtable discussions, clinical protocols, and best practices. Therapeutic Hypothermia and Temperature Management is the journal of record, published online with Open Access options and in print. Tables of content and a sample issue may be viewed on the Therapeutic Hypothermia and Temperature Management website at http://www.liebertpub.com/ther.
See original here:
Is therapeutic hypothermia beneficial in all patients following cardiac arrest?
PUBLIC RELEASE DATE:
25-Feb-2014
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, February 25, 2014Repeated concussions and mild brain trauma can result in reduced levels of growth hormone, gonadotropin, and testosterone, causing disorders such as metabolic syndrome and erectile dysfunction and overall poor quality of life. The results of a new study of retired professional football players that compares number of concussions sustained during their careers and health problems associated with hormonal deficiency is published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Neurotrauma website at http://www.liebertpub.com/neu.
In the article "Prevalence of pituitary hormone dysfunction, metabolic syndrome and impaired quality of life in retired professional football players: a prospective study," the authors report that more than 50% of the retired players evaluated for growth hormone deficiency, hypogonadism, and quality of life had suffered at least three concussions during their careers in the National Football League. Repeat concussion is common in the NFL.
John T. Povlishock, PhD, Editor-in-Chief of Journal of Neurotrauma and Professor, Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, notes that "although as emphasized by the authors, this study awaits further confirmation with expanded sample sizes and a more critical linkage to a history of concussion intensity and intervals between the concussive injuries, the findings are of considerable interest. Importantly, this study moves us away from the singular focus that repetitive concussive brain injuries ultimately lead to chronic traumatic encephalopathy to the premise that such injuries can elicit pituitary dysfunction and metabolic syndrome that may be significant contributors to a poor quality of life in a subset of professional athletes."
###
Contact:
Vicki Cohn Mary Ann Liebert, Inc., publishers 914-740-2100 vcohn@liebertpub.com
About the Journal
Read more:
New study finds concussion-related health problems in retired football players
Genetic engineering genes proteomics gene bioinformatics
By: Iridium
Read the original post:
Genetic engineering genes proteomics gene bioinformatics - Video
PUBLIC RELEASE DATE:
24-Feb-2014
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, February 24, 2014Over the past three funding stages, the European Commission has invested nearly $475 million in 100 projects in the gene transfer and gene therapy field. David Gancberg, Directorate-General for Research and Innovation, European Commission (Brussels), describes the substantial opportunities for funding to support basic and clinical research in gene and cell therapy to find new treatments for chronic and rare diseases and novel regenerative medicine approaches in a Commentary article in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website.
Dr. Gancberg and co-author Ruxandra Draghia-Akli state, "More than ever, the European Union offers to the gene and cell therapy sectors the possibilities of financial support to bright and innovative consortia ready to develop, possibly in collaboration with industry, new therapeutic applications to be tested in clinical trials, or novel products for the market, and build sustainable networks of expertise in the field," in their article "Gene and Cell Therapy Funding Opportunities in Horizon 2020: An Overview 2014-2015."
"Funding for gene therapy provided by the European Commission over the last decade has been critical to the current success we are seeing in the clinics. The commentary provided by doctors Gancberg and Draghia-Akli describe exciting new programs." says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
###
About the Journal
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
See the original post here:
Exclusive David Gancberg article in Human Gene Therapy